As a large multi-national pharma enterprise, Astellas covers more than 70 countries and regions all over the world. Since entering into China market in 1994, Astellas has been devoting to providing high-quality innovative products and services to improve the health and well-being of Chinese people. Now, we are aiming to play a leading role in oncology and specialty care in China.
We have witnessed the great changes brought by reform and opening up in China in the last 29 years. Especially in the past 10 years, the accelerated drug review and approval system enables faster patient access to innovative drugs. And global pharmaceutical innovators are able to introduce their innovative drugs to China at a faster pace. It helps propel further pharmaceutical innovation. Chinese patients have improved access to global cutting-edge innovative therapies and benefit from them.
In the past 10 years, China has been becoming more and more important for Astellas. With our vision of standing on the forefront of healthcare change to turn innovative science into value for patients, Astellas set up Astellas Greater China Region in 2019, as well as upgraded reporting lines and adjusted layout planning, representing the group highly valued China market, and reflecting strong development momentum and continuous growth in global position of China market. China has risen to the top tier of Astellas' global strategic markets based on its rapid growth and potential.
In 2021, Astellas China upgraded the structure, with the regional headquarters of Greater China region established in Beijing. After upgrading, the new structure consists of one headquarter and two centers now. Astellas Investment is the regional headquarter of Greater China, it will play a critical role in the overall layout, strategic decision, and resource coordination to support the company’s development in all aspects; Beijing Astellas Medical will be responsible for the sales and marketing of oncology and specialized treatment products in China; and Astellas Pharma will further focus on production and manufacturing. With this upgrade, China becomes one of the most important strategic markets for Astellas global.
The new structure is to implement agile decision-making and lean management. The three business entities will be united to inject new momentum for Astellas' development in the Greater China Region. Our focus is breakthroughs in oncology, innovative drugs and therapies. To achieve the goal, we will continue to accelerate the introduction of our innovative drugs into China. We will also continue to improve access and affordability of innovative drugs for Chinese patients, and channel our energies into providing faster and more efficient value for Chinse patients. We will also work together with all the stakeholders in China, together contributing to the early achievement of Healthy China 2030.
The story is provided by Astellas China.
